Viridien says JPMorgan Chase beneficial stake falls to 4.80%

Virios Therapeutics, Inc.
Jpmorgan Chase

Virios Therapeutics, Inc.

VIRI

0.00

Jpmorgan Chase

JPM

0.00
  • JPMorgan Chase cut its stake in Viridien below the 5% threshold on May 12.
  • The bank held 345,331 shares, equal to 4.8% of share capital, 4.79% of voting rights.
  • The move followed open-market sales.
  • J.P. Morgan Securities plc also reported exposure via 27 cash-settled equity swap contracts linked to 336,049 shares, with maturities running from July 2, 2026 to May 16, 2033.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viridien SA published the original content used to generate this news brief on May 18, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.